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Abstract Psoriasis vulgaris is a complex chronic skin dis-
ease with immunological and genetic background. The most
important predisposing genetic factors in psoriasis are genes
of the human leukocyte antigen (HLA) region. Accumula-
tive evidence has shown that several HLA alleles are closely
associated with psoriasis; however, they tend to vary in
different racial and ethnic backgrounds. One hundred
forty-seven unrelated Slovak patients with psoriasis vulgaris
(average age at onset 28±14 years) were genotyped for the
HLA-C, DQB1 and DRB1 alleles by the polymerase chain
reaction using sequence-specific primers. Allele frequencies
observed in the group of psoriatic patients were compared to
those obtained in the ethnically matched control group com-
prising 194 subjects with no history of psoriasis. Suscepti-
bility to psoriasis vulgaris in our study group is significantly
associated with HLA-C*06 (odds ratio (OR)03.85),
DRB1*07 (OR02.56) and DQB1*02 (OR01.09), respec-
tively, whereas DRB*01 (OR00.05) is associated negative-
ly. Hereby, we provide the first report on the association of
HLA-C, DRB1 and DQB1 alleles with psoriasis in the
Slovak population. Our findings confirm HLA-C*06 and
DRB1*07 as the most important genetic risk factors for
psoriasis. However, the role of HLA genes as causative in
the pathogenesis of the disease remains unclear. Identifica-
tion of genetic factors that increase the risk of psoriasis is a
precondition that helps to elucidate the pathogenesis of this
troubling disease and identify targets for a more specific and
effective therapy.
Introduction
Psoriasis vulgaris (PV) is a common chronic skin disease
with a worldwide distribution, affecting 1–3 % of the gen-
eral population (Henseler 1998; Kurd and Gelfand 2009).
Like many other immune-mediated diseases, psoriasis
results from a combined action of multiple genes and envi-
ronmental triggers. The age at disease onset is highly vari-
able; however, studies have shown that 75–90 % of patients
develop psoriasis before the age of 40, with a peak around
puberty and a smaller peak around 50–60 years of age
(Henseler and Christophers 1985). Among psoriatic
patients, up to 40 % develop psoriatic arthritis (PsA)—an
associated inflammation of the joints (Weger 2010).
The human leukocyte antigen (HLA) region on chromo-
some 6p21 is well known to carry the most important
genetic factors in the susceptibility to psoriasis, whereas
the critical segment appears to be a 300-kb interval at the
centromeric end of HLA class I, named PSORS1 (Nair et al.
2000; Martinez-Borra et al. 2003). The first reports on the
association of both HLA class I and class II antigens (e.g.
HLA-B13, B17, DR7) with psoriasis were obtained by
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serologic methods already in the 1970s (Russel et al. 1972;
Brenner et al. 1978). In the following years, molecular
genotyping was introduced, and many independent groups
have proven that among HLA alleles, HLA-C*06 confers
the major and most consistently demonstrated risk factor
(Elder et al. 1994; Szczerkowska-Dobosz 2005; Pasic et al.
2009). HLA-C*06 carriers have a significantly higher risk
of developing PV with risk ratios ranging in Caucasoid
psoriatic patients from 3 to 36 (Cassia et al. 2007). However,
not all HLA-C*06 psoriasis-associated haplotypes appear to
confer an equal risk of PV in different populations as
reviewed by Elder et al. (2001). Multiple HLA alleles have
been identified in increased occurrence rates, most probably
because of linkage disequilibrium in the HLA region. In the
German, Italian and Thai population, the extended haplo-
type (EH) HLA-C*06-B57-DRB1*0701-DQA1*0201-
DQB1*0303, named according to the B allele EH-57.1,
was reported to be highly overrepresented in patients with
psoriasis (Schmitt-Egenolf 1996; Choonhakarn et al. 2002).
Another similar predisposing haplotype, HLA-C*0602-
B57-DRB1*0701-DQA1*0201-DQB1*0201 (EH-57.2),
was observed in Croatian patients (Kastelan et al. 2003).
However, many of the associated alleles tend to vary among
patients of different racial and ethnic backgrounds as
reviewed by Cassia et al. (2007).
The aim of our study was to provide the first survey of
the HLA-C as well as HLA-DRB1* and DQB1* allele
distribution in Slovak psoriatic patients as a contribution to
the precise definition of HLA class I- and class II-associated
loci in different ethnic populations.
Materials and methods
Study group
One hundred forty-seven unrelated patients with chronic
stable plaque PV were included in the study. They were
recruited at random via several outpatient dermatovenereol-
ogy clinics in Slovakia. Detailed clinical parameters of the
study group were recorded by the dermatologists, and they
are summarized in Table 1. Mean age at disease onset was
28 years (range 7–67, standard deviation (SD)±14). Of the
patients, 82.3 % had disease onset before 40 years of age
and 17.6 % after 40. Severity and extent of the disease were
estimated using the scoring system Psoriasis Area and Se-
verity Index (PASI). The average PASI score was 22±17.
According to the criteria proposed by Henseler and
Christophers (1985), patients may be subdivided into two
subsets: type I psoriasis (age at onset before 40, presence of
a positive family history and strong association with HLA-
C*06) and type II (age at onset after 40, no family history and
weak association with HLA-C*06). At first, we have
subdivided our patients into subsets according to the follow-
ing criteria: age of onset ≤40 versus >40 years and/or a
positive family history of psoriasis versus negative history.
Family history was considered positive when at least one first-
or second-degree relative had psoriasis. No statistically sig-
nificant differences were found when comparing the HLA
allele frequencies observed in those subsets (data not shown).
Similarly, we have divided our patients into a subset with
psoriatic arthritis (46.3 % of the psoriatic patients) and a
subset without signs of PsA (remaining 53.7 % of subjects).
Again, no significant differences in frequencies were ob-
served between the PsA-positive versus PsA-negative sub-
sets. Therefore, we decided to report our results on the
whole group of our psoriatic patients regardless of the
above-mentioned criteria (Table 1).
Population controls
The reference group comprised 194 unrelated subjects without
a history of PV who were randomly recruited from blood and
bone marrow donors. Data on the control subjects have been
reported elsewhere (Cechova et al. 1998; Kulcsarova et al.
2000). All patients and controls were Caucasoids of Slovak
descent. Slovakia is a Central European country with ethni-
cally homogenous population. Romanies who constitute a
fraction of about 5 % were not included in this study.
A written informed consent for enrolling in the study and
for personal data management was obtained from all patients
and control subjects. All investigations were carried out in
accordance with the principles of the Declaration of Helsinki.
HLA typing
Both HLA class I and class II alleles were determined by
molecular typing that proved superior to serological meth-
ods due to higher specificity and sensitivity (Bunce et al.
1996). DNA was extracted from whole blood using a mod-
ified salting-out procedure (Miller et al. 1988). Genotyping
was performed using the PCR-SSP technique according to
the 12th Workshop protocol using Olerup SSP® HLA-C low
Table 1 Characteristics of the study group
Parameter Psoriatic subjects (n0147)
Gender ratio M/F 95/52
Mean age ± SD (years) 47±12
Mean onset age ± SD (years) 28±14
Onset at ≤40/>40 years 121/26
Familiar occurrence +/− 67/80
Psoriatic arthritis +/− 68/79
Average PASI score ± SD 22±17
SD standard deviation, PASI Psoriasis Area and Severity Index
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resolution, resp. DQ-DR SSP Combi Tray (Olerup SSPAB,
Sweden) (Olerup and Zetterquist 1992; Olerup et al. 1993).
Amplification reactions were prepared according to manu-
facturers’ protocols, and electrophoresis was performed in a
1.5 % agarose gel for 20 min at 10 V/cm.
Statistical analysis
Allele frequencies in the study group and in the controls were
evaluated by direct counting. Data were tested for the goodness
of fit between the observed and expected genotype frequen-
cies, and no deviations from the Hardy–Weinberg equilibrium
were found. Associations of particular alleles with psoriasis
were expressed as odds ratios (OR) with 95 % confidence
intervals (CI) calculated according to Woolf’s formula. Statis-
tical significance of these associations was assessed using theP
values defined by the two-sided Fisher’s exact test. As multiple
comparisons were made, Bonferroni’s correction was applied
multiplying the obtained P values by the number of alleles
considered at each locus (Pcor). The level of significance was
set at Pcor<0.01. All calculations were performed using the
data analysis and graphing software OriginPro version 8.1.
Results
The investigated HLA class I and class II allelic frequencies
observed in 147 patients with PV and in the control group
are given in Tables 2, 3 and 4. Differences between the
cohorts were expressed by odds ratios and Pcor values. They
are indicated in the tables only when statistically significant,
i.e. when the P value corrected for the number of alleles
considered at each locus was <0.01.
As may be seen in Table 2, the strongest association among
HLA-C alleles is conferred by the C*06 allele. The allelic
frequency of C*06 was 23.5 % in patients compared to 7.5 %
in controls, which is an extremely statistically significant
difference (OR03.85, Pcor00.000025). Out of the HLA-
DRB1 alleles presented in Table 3, only DRB1*07 was pos-
itively associated with the disease, showing a frequency of
28.9 % in the patients versus 13.9 % in the control group. This
association is again extremely statistically significant (OR0
2.56, Pcor00.000019). On the contrary, the DRB1*01 allele
was associated with PV negatively (OR00.32, Pcor00.0097).
Out of the DQB1 alleles, the DQB1*02 was observed to have
a significantly increased frequency in the patients (29.3 %
versus 19.1 %, OR01.09, Pcor00.0095) as shown in Table 4.
We have divided our 147 patients into two subsets accord-
ing to the presence (46.3 %) versus absence (53.7 %) of
psoriatic arthritis. No statistically significant differences in
the investigated HLA allele frequencies were observed be-
tween the two cohorts. On the contrary, significant differences
were noted when each of the two subsets was compared with
population controls, namely a strong positive association of
HLA-C*06 with psoriasis with the presence of PsA (OR0
3.94, Pcor<0.0001) and a slightly weaker association with
psoriasis alone (OR03.72, Pcor<0.0001). Similarly, there was
a statistically significant association of HLA-DRB1*07 with
psoriasis+PsA (OR02.75, Pcor<0.0001) and a weaker associ-
ation with psoriasis without PsA (OR02.27, Pcor00.002).
Discussion
Although the aetiology of psoriasis vulgaris is still un-
known, there is a common consensus that it is a complex
Table 2 Distribution of HLA-C
alleles in patients with psoriasis
and controls
OR odds ratio, CI confidence
interval, Pcor corrected P value,
n.s. not significant
HLA-C Psoriasis vulgaris (2n0294) Controls (2n0214) OR 95 % CI Pcor
Count f (%) Count f (%)
*01 13 4.42 13 6.07 0.71 0.32–1.59 n.s.
*02 11 3.74 12 5.61 0.66 0.28–1.52 n.s.
*03 24 8.16 19 8.88 0.92 0.49–1.72 n.s.
*04 42 14.29 34 15.89 0.88 0.54–1.45 n.s.
*05 10 3.40 9 4.21 0.80 0.32–2.00 n.s.
*06 69 23.47 16 7.48 3.85 2.13–6.67 <0.0001
*07 50 17.01 58 27.10 0.55 0.36–0.85 n.s.
*08 2 0.68 7 3.27 0.20 0.04–0.99 n.s.
*12 52 17.69 32 14.95 1.22 0.76–2.00 n.s.
*14 1 0.34 0 0 2.19 0.09–54.12 n.s.
*15 4 1.36 3 1.40 0.97 0.22–4.35 n.s.
*16 13 4.42 4 1.87 2.44 0.78–7.69 n.s.
*17 1 0.34 5 2.34 0.14 0.02–1.23 n.s.
*18 2 0.68 2 0.93 0.72 0.10–5.26 n.s.
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disorder occuring in a sensitive genetic territory. Multiple
genes seem to be involved in the pathogenesis of psoriasis;
however, the major genetic determinant is located within the
PSORS1 segment of the HLA region on chromosome
6p21.3, as reported by several independent groups (Nair et
al. 2000; Martinez-Borra et al. 2003).
Our study confirmed the strong positive association of
psoriasis with HLA-C*06, observed mainly in Caucasoid
populations as well as in several other ethnically different
groups. There are only a few studies from oriental popula-
tions, e.g. the Japanese reported association with other
HLA-C alleles, most often with the HLA-C*07 allele
(Roitberg-Tambur et al. 1994; Asahina et al. 1996). Inter-
estingly, the occurrence rate of HLA-C*07 was increased
also in our psoriatic patients, though only on the edge of the
statistical significance (Pcor00.07).
The HLA-C*06 allelic frequency of 23.5 % observed in
our psoriatic subjects (compared to 7.5 % in the controls)
highly corresponds with that of 23.9 % observed in the PV
patients of neighbouring Poland and fits into the general
image seen in the Central European geographic region
(Szczerkowska-Dobosz et al. 1996; Łuszczek et al. 2003).
Though HLA-C*06 is undoubtedly associated with PV,
limited data exist to explain the functional role of HLA-C in
the pathogenesis of psoriasis. According to many researchers,
it is unlikely that HLA-C itself is the susceptibility gene (Elder
et al. 2001; Orru et al. 2005; Pasic et al. 2009). HLA-C is most
probably a marker of another closely linked gene, or a block of
genes at a distinct locus. Thus, major effort has been put into
the identification of candidate genes close to HLA-C such as
the corneodesmosin gene, which encodes an adhesive protein
expressed by keratinocytes or the alpha-helix coiled-coil rod
homologue gene. However, there is a lack of evidence con-
firming their direct involvement in the development of psori-
asis, and none of the candidates are convincingly associated
with psoriasis independent of HLA-C (Tazi-Ahnini et al.
1999; O’Brien et al. 2001; Capon et al. 2002, 2003).
The HLA-C*06 allele is the only genetic variant repeat-
edly observed to be associated with the phenotypic features
of PV, especially with an early onset of the disease as
confirmed among others by Szczerkowska-Dobosz et al.
(2004). According to Henseler and Christophers (1985),
patients may be classified into two distinct types: type I
(age at disease onset before 40 years, familial occurrence
Table 3 Distribution of HLA-
DRB1 alleles in patients with
psoriasis and controls
OR odds ratio, CI confidence
interval, Pcor corrected P value,
n.s. not significant
HLA-DRB1 Psoriasis vulgaris (2n0294) Controls (2n0388) OR 95 % CI Pcor
Count f (%) Count f (%)
*01 11 3.74 42 10.82 0.32 0.16–0.64 <0.001
*03 20 6.80 31 7.99 0.84 0.47–1.52 n.s.
*04 26 8.84 35 9.02 0.98 0.57–1.67 n.s.
*07 85 28.91 54 13.93 2.56 1.72–3.70 <0.0001
*08 8 2.72 10 2.58 1.05 0.41–2.70 n.s.
*09 2 0.68 1 0.26 2.63 0.24–33.33 n.s.
*10 4 1.36 4 1.03 1.33 0.33–5.26 n.s.
*11 36 11.57 63 16.24 0.72 0.46–1.12 n.s.
*12 13 4.42 5 1.29 3.57 1.25–10.00 n.s.
*13 38 12.93 56 14.43 0.88 0.56–1.37 n.s.
*14 11 3.74 11 2.83 1.33 0.57–3.13 n.s.
*15 23 7.82 52 13.40 0.55 0.33–0.92 n.s.
*16 19 6.47 24 6.18 1.05 0.56–1.96 n.s.
Table 4 Distribution of HLA-
DQB1alleles in patients with
psoriasis and controls
OR odds ratio, CI confidence
interval, Pcor corrected P value,
n.s. not significant
HLA-DQB1 Psoriasis vulgaris Control subjects OR 95 % CI Pcor
(2n0294) (2n0388)
Count f (%) Count f (%)
*05 51 17.35 85 21.91 0.66 0.45–0.97 n.s.
*06 50 17.00 92 23.71 1.75 1.23–2.50 n.s.
*02 86 29.25 74 19.07 1.09 0.79–1.49 <0.01
*03 103 35.04 129 33.25 0.66 0.20–2.22 n.s.
*04 4 1.36 8 2.06 0.75 0.51–1.10 n.s.
322 Folia Microbiol (2013) 58:319–324
and high frequency of HLA-C*06) and type II psoriasis
(age at onset after 40, occuring sporadically, character-
ized by a weak association with HLA-C*06). However, it
proved difficult to classify our subjects as either having
the type I or type II psoriasis as many patients were in
an intersection of the two types showing features of both
groups, and thus, we failed to confirm this observation.
Comparison of the two types was also limited by the fact
that we had only a relatively small fraction of late-onset
patients (17.6 %).
In order to determine whether HLA-C*06 and, respec-
tively, other alleles are associated with PsA itself or primar-
ily with psoriasis, we have compared the allele frequencies
obtained in psoriatic patients with PsA with frequencies in
patients having psoriasis alone. Our results suggest that the
primary association with HLA-C*06 and HLA-DRB1*07 is
with psoriasis and not with PsA per se.
Significant overrepresentation of the neighbouring HLA
class II alleles, namely the DRB1*07 and DQB1*02 in our
study group, is most probably due to the fact that they are
contained within the same extended haplotype. This partic-
ular risk haplotype was observed also in Croatian psoriasis
patients and was named EH-57.2 (Kastelan et al. 2003).
Many authors have reported some alleles that occur in
lower occurrence rates in patients with PV, indicating they
may have a protective effect (Cassia et al. 2007; Kundakci et
al. 2002; Łuszczek et al. 2003). The only allele with a
significantly decreased frequency in our patients was the
HLA-DRB1*01 (OR00.32, Pcor<0.001). However, as the
palette of published “protective” alleles is very variegated
and they show only mild association, we assume that they
occur at the expense of the highly overrepresented predis-
posing alleles.
In conclusion, our study provides the first report on HLA
class I and class II allele association with psoriasis vulgaris in
the Slovak population. Our data point toward the alleles HLA-
C*06, DRB1*07 and DQB1*02, respectively, as major genet-
ic risk factors for PV. Precise identification of genetic factors
that increase the risk of psoriasis and psoriatic arthritis will
help to elucidate the pathogenesis of this troubling disease and
identify targets for a more specific and effective therapy.
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